erythrosine and Brain Hemorrhage, Cerebral, Traumatic

erythrosine has been researched along with Brain Hemorrhage, Cerebral, Traumatic in 1 studies

Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.

Research

Studies (1)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Number of Patients Who Died During the 90-day Study Period

Mortality at any time from randomization through day-90 (NCT01662895)
Timeframe: 90 days

Number of Patients With Hypotension

(NCT01662895)
Timeframe: within 7 days or discharge

Number of Patients With New Visual or Auditory Changes

(NCT01662895)
Timeframe: within 7 days or discharge

Number of Patients With Serious Adverse Events

(NCT01662895)
Timeframe: 90 days

Number of Subjects With Acute Respiratory Distress Syndrome

(NCT01662895)
Timeframe: 90 days

Number of Subjects With Allergic/Anaphylactic Reaction

(NCT01662895)
Timeframe: within 7 days or discharge

Number of Subjects With Modified Rankin Scale (mRS) Score 0-2

"The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.~The minimum mRS score is 0 (i.e. no disability). The maximum score is 6 (i.e. dead)." (NCT01662895)
Timeframe: 90 days

Number of Subjects With mRS Score 0-3

The proportion of DFO- and placebo-treated subjects with mRS 0-3 vs. 4-6 at 90 days (NCT01662895)
Timeframe: 90 days

Other Studies

1 other study available for erythrosine and Brain Hemorrhage, Cerebral, Traumatic